ATE551069T1 - Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung - Google Patents

Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung

Info

Publication number
ATE551069T1
ATE551069T1 AT03725536T AT03725536T ATE551069T1 AT E551069 T1 ATE551069 T1 AT E551069T1 AT 03725536 T AT03725536 T AT 03725536T AT 03725536 T AT03725536 T AT 03725536T AT E551069 T1 ATE551069 T1 AT E551069T1
Authority
AT
Austria
Prior art keywords
compositions
fusion polypeptide
polypeptide vaccines
mucin fusion
mucin
Prior art date
Application number
AT03725536T
Other languages
English (en)
Inventor
Jan Holgersson
Original Assignee
Recopharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recopharma Ab filed Critical Recopharma Ab
Application granted granted Critical
Publication of ATE551069T1 publication Critical patent/ATE551069T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT03725536T 2002-04-22 2003-04-22 Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung ATE551069T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37509502P 2002-04-22 2002-04-22
PCT/IB2003/002207 WO2003088995A2 (en) 2002-04-22 2003-04-22 Mucin fusion polypeptide vaccines, compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE551069T1 true ATE551069T1 (de) 2012-04-15

Family

ID=29251230

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03725536T ATE551069T1 (de) 2002-04-22 2003-04-22 Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung

Country Status (8)

Country Link
US (2) US8034351B2 (de)
EP (1) EP1517700B1 (de)
JP (1) JP2005530493A (de)
AT (1) ATE551069T1 (de)
AU (1) AU2003228067B2 (de)
CA (1) CA2483473A1 (de)
ES (1) ES2385032T3 (de)
WO (1) WO2003088995A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020110841A1 (en) 2000-12-22 2002-08-15 KUFE Donald W. Regulation of cell growth by MUC1
US20040009546A1 (en) * 2002-04-22 2004-01-15 Jan Holgersson Compositions and methods for inhibiting microbial adhesion
US8129506B2 (en) 2003-10-24 2012-03-06 Genzyme Corporation Modulation of the interaction of MUC1 with MUC1 ligands
JP4549666B2 (ja) * 2003-12-12 2010-09-22 タカラバイオ株式会社 抗体の製造方法
US7807636B1 (en) 2004-11-12 2010-10-05 Wisconsin Alumni Research Foundation Bovine P-selectin glycorpotein ligand-1
ATE527285T1 (de) 2005-01-28 2011-10-15 Univ Ramot Anti-muc1-alpha-beta-antikörper
FR2886298A1 (fr) * 2005-05-24 2006-12-01 Ifremer Anticorps ou fragment d'anticorps couple a un agent immunogene
US20070184063A1 (en) * 2006-01-23 2007-08-09 Jan Holgersson Production of Proteins Carrying Oligomannose or Human-Like Glycans in Yeast and Methods of Use Thereof
ES2502966T3 (es) * 2006-01-26 2014-10-06 Recopharma Ab Composiciones y métodos para inhibir la adhesión viral
US7871784B2 (en) 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
WO2008097840A2 (en) 2007-02-02 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of muc1 by hsf1 and stat3
US9662383B2 (en) * 2007-03-26 2017-05-30 University Of Massachusetts Compositions and methods for increasing immunogenicity of glycoprotein vaccines
US20090280104A1 (en) * 2008-05-09 2009-11-12 Recopharma Ab Compositions and methods for inhibiting shiga toxin and shiga-like toxin
AU2009251328B2 (en) 2008-05-30 2014-10-02 Glycofi, Inc. Yeast strain for the production of proteins with terminal alpha-1,3-linked galactose
CA2821969A1 (en) * 2010-12-21 2012-06-28 Recopharma Ab Tear substitutes
PL2859015T3 (pl) 2012-06-08 2018-08-31 Alkermes, Inc. Ligandy modyfikowane przez permutację kołową jako agoniści i antagoniści
CN104800838B (zh) * 2015-04-14 2018-01-09 深圳市中联生物科技开发有限公司 MUC1‑Fc多肽疫苗及其制备方法和应用
JP6441167B2 (ja) * 2015-05-15 2018-12-19 愛三工業株式会社 蒸発燃料処理装置
WO2019031938A2 (ko) * 2017-08-10 2019-02-14 주식회사 굳티셀 암 치료를 위한 t 세포의 활성화 방법
AU2022241762A1 (en) 2021-03-24 2023-09-14 Mural Oncology, Inc. Upar antibodies and fusion proteins with the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4710761A (en) 1985-07-09 1987-12-01 American Telephone And Telegraph Company, At&T Bell Laboratories Window border generation in a bitmapped graphics workstation
EP0454781B1 (de) 1989-01-23 1998-12-16 Chiron Corporation Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE69019609T2 (de) * 1989-07-07 1995-11-30 Takeda Chemical Industries Ltd Proteine und deren Herstellung.
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
KR950703640A (ko) 1992-10-09 1995-09-20 가일 케이,나우톤. 간 보존 세포(liver reserve cells)
US5516964A (en) * 1994-01-21 1996-05-14 Sun Company, Inc. (R&M) Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal
AU2158995A (en) 1994-03-15 1995-10-03 Medical College Of Pennsylvania And Hahnemann University Compositions and methods for vaccines comprising alpha-galactosyl epitopes
AUPN568095A0 (en) * 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
US6090381A (en) * 1997-02-11 2000-07-18 Immunomedics, Inc. Stimulation of an immune response with antibodies labeled with the . .alpha-galactosyl epitope
SE9701127D0 (sv) * 1997-03-26 1997-03-26 Karolinska Innovations Ab Antigenic fusionprotein carrying GALal, 3GAL epitopes

Also Published As

Publication number Publication date
US8034351B2 (en) 2011-10-11
AU2003228067B2 (en) 2008-05-29
AU2003228067A1 (en) 2003-11-03
CA2483473A1 (en) 2003-10-30
US20120034220A1 (en) 2012-02-09
EP1517700B1 (de) 2012-03-28
US20040002585A1 (en) 2004-01-01
ES2385032T3 (es) 2012-07-17
WO2003088995A3 (en) 2004-06-03
EP1517700A2 (de) 2005-03-30
WO2003088995A2 (en) 2003-10-30
JP2005530493A (ja) 2005-10-13

Similar Documents

Publication Publication Date Title
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
FR20C1016I1 (de)
DK1584685T3 (da) Tumorassocieret antigenderivater fra Mage-familien, anvendt til fremstilling af fusionsproteiner med T-hjælper epitoper og sammensætninger til vaccination
CY1119106T1 (el) Αντισωματα εναντι masp-2
CY1108083T1 (el) Αντιγονα και συνθεσεις του neisseria meningitidis
UA93855C2 (ru) Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
ATE405647T1 (de) Rekombinantes gelatin in impstoffen
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
EP1594536A4 (de) Adjuvante influenza-vakzine
ATE481108T1 (de) Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DK1259547T3 (da) Højpotente, rekombinante antistoffer og fremgangsmåde til fremstilling heraf
UA85536C2 (en) Viral antigens
DK1530637T3 (da) Carlsberg-subtilisin-proteiner med nedsat immunogenitet
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
ATE370745T1 (de) Verbesserte polysaccharid- und glykokonjugat- vakzine
NO20011537L (no) Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes
EP1565080A4 (de) Neue immunogene proteine von leptospira
WO2005037236A3 (en) Novel heat shock protein 20-related polypeptides and uses therefor
WO2003093298A3 (en) Immunogenic peptides
DK1444356T3 (da) Identifikation af epitoper og mindskelse af allergeniciteten af fødevareproteiner
DK1578772T3 (da) Cytokiner og cytokinreceptorer med reduceret immunogenicitet
ATE414540T1 (de) Impfstoffe gegen allergien
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
GB0409559D0 (en) Polypeptide